API | mirikizumab

mirikizumab (Omvoh) Report issue

Biologics mAb Approved ^FDA

AACT

Active Ingredient History

NOW

Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Interleukin-23 subunit alpha (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

ly3074828 | mirikizumab

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Colitis, Ulcerative (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Healthy Volunteers (Phase 1)

Inflammatory Bowel Diseases (Phase 3)

Psoriasis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 33
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue